ATE456100T1 - Zusammensetzungen und verfahren im zusammenhang mit der nuklearen hormon-rezeptor-stelle ii - Google Patents

Zusammensetzungen und verfahren im zusammenhang mit der nuklearen hormon-rezeptor-stelle ii

Info

Publication number
ATE456100T1
ATE456100T1 AT03765637T AT03765637T ATE456100T1 AT E456100 T1 ATE456100 T1 AT E456100T1 AT 03765637 T AT03765637 T AT 03765637T AT 03765637 T AT03765637 T AT 03765637T AT E456100 T1 ATE456100 T1 AT E456100T1
Authority
AT
Austria
Prior art keywords
site
nhrs
modulators
nuclear hormone
methods
Prior art date
Application number
AT03765637T
Other languages
English (en)
Inventor
Arthur Doweyko
Steven Nadler
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ATE456100T1 publication Critical patent/ATE456100T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/30—Drug targeting using structural data; Docking or binding prediction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Evolutionary Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
AT03765637T 2002-07-18 2003-07-17 Zusammensetzungen und verfahren im zusammenhang mit der nuklearen hormon-rezeptor-stelle ii ATE456100T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39690702P 2002-07-18 2002-07-18
PCT/US2003/022299 WO2004009016A2 (en) 2002-07-18 2003-07-17 Compositions and methods involving nuclear hormone receptor site ii

Publications (1)

Publication Number Publication Date
ATE456100T1 true ATE456100T1 (de) 2010-02-15

Family

ID=30770956

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03765637T ATE456100T1 (de) 2002-07-18 2003-07-17 Zusammensetzungen und verfahren im zusammenhang mit der nuklearen hormon-rezeptor-stelle ii

Country Status (7)

Country Link
US (1) US7442554B2 (de)
EP (1) EP1575502B1 (de)
AT (1) ATE456100T1 (de)
AU (1) AU2003251969A1 (de)
DE (1) DE60331103D1 (de)
ES (1) ES2337679T3 (de)
WO (1) WO2004009016A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0316290D0 (en) 2003-07-11 2003-08-13 Glaxo Group Ltd Novel compounds
JP2006528617A (ja) * 2003-07-24 2006-12-21 ファーマジーン ラボラトリーズ リミテッド ５−ｈｔ２ｂ受容体アンタゴニスト
WO2005097113A2 (en) * 2004-04-08 2005-10-20 Pharmagene Laboratories Limited 5-ht2b receptor antagonists
PE20060272A1 (es) 2004-05-24 2006-05-22 Glaxo Group Ltd (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
JP5281291B2 (ja) 2005-01-10 2013-09-04 グラクソ グループ リミテッド 新規化合物
MY145281A (en) 2005-03-25 2012-01-13 Glaxo Group Ltd Novel compounds
UY29439A1 (es) 2005-03-25 2006-10-02 Glaxo Group Ltd Nuevos compuestos
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
JP2011503081A (ja) 2007-11-01 2011-01-27 ブリストル−マイヤーズ スクイブ カンパニー グルココルチコイド受容体、ＡＰ−１および／またはＮＦ−κＢ活性の調節剤として有用な非ステロイド性化合物、並びにその使用
US20120272951A1 (en) 2009-12-16 2012-11-01 3M Innovative Properties Company Formulations and methods for controlling mdi particle size delivery

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5759785A (en) * 1992-05-14 1998-06-02 Baylor College Of Medicine Method of identifying hormone antagonists and agonists
US5856116A (en) * 1994-06-17 1999-01-05 Vertex Pharmaceuticals, Incorporated Crystal structure and mutants of interleukin-1 beta converting enzyme
JP2000502086A (ja) * 1995-12-13 2000-02-22 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 核レセプターのリガンドおよびリガンド結合ドメイン
CA2323575A1 (en) * 1998-03-30 1999-11-25 Regents Of The University Of California Methods and compounds for modulating nuclear receptor coactivator binding
AU2818200A (en) 1999-03-01 2000-09-21 Karo Bio Ab Homology models of the glucocorticoid receptor
AU2002355929A1 (en) * 2001-07-17 2003-03-03 Smithkline Beecham Corporation Crystallized glucocorticoid receptor ligand binding domain polypeptide and screening methods employing same
GB0209507D0 (en) * 2002-04-25 2002-06-05 Karobio Ab Nuclear receptor structure
EP1375517A1 (de) * 2002-06-21 2004-01-02 Smithkline Beecham Corporation Struktur der Ligandenbindedomäne des Glucocorticoidrezeptors umfassend eine expandierte Bindetasche und Anwendungsverfahren
JP2006508042A (ja) 2002-07-18 2006-03-09 ブリストル−マイヤーズ　スクイブ　カンパニー グルココルチコイド受容体の修飾物質および方法

Also Published As

Publication number Publication date
US20060223110A1 (en) 2006-10-05
WO2004009016A3 (en) 2005-10-06
ES2337679T3 (es) 2010-04-28
EP1575502B1 (de) 2010-01-20
AU2003251969A1 (en) 2004-02-09
WO2004009016A2 (en) 2004-01-29
US7442554B2 (en) 2008-10-28
EP1575502A4 (de) 2007-01-03
EP1575502A2 (de) 2005-09-21
DE60331103D1 (de) 2010-03-11
AU2003251969A8 (en) 2004-02-09

Similar Documents

Publication Publication Date Title
DE60336901D1 (de) Chinazolinon modulatoren von nukleinrezeptoren
DE60331103D1 (de) Zusammensetzungen und verfahren im zusammenhang mit der nuklearen hormon-rezeptor-stelle ii
Ozturk et al. Crash frequency modeling for highway construction zones
DK1791868T3 (da) Antistoffer, der binder til receptorer KIR2DL1, -2, 3 men ikke KIR2DS4, samt terapeutisk anvendelse
HUP0105337A2 (hu) Az immunválaszban szerepet játszó új polipeptidek
Piotrovsky et al. Galantamine population pharmacokinetics in patients with Alzheimer's disease: modeling and simulations
Schaller et al. Evaluation of the drug‐drug interaction potential of treosulfan using a physiologically‐based pharmacokinetic modelling approach
Achten Normative positions in architectural design-deriving and applying design methods
Thrane et al. Simulation and verificaiton of flow in test methods
Fraser et al. Paleoearthquake investigation of the Waimea-Flaxmore fault system, Nelson, New Zealand
Benjamin The aesthetics of ‘the ground up’city:: Some insights from Bangalore
O'Neill Labour hire: issues and responses
AbuKrisha New 2D simulation of TBM tunneling and application on EL-AZHAR road tunnels
Buchanan Robert Willis on Cambridge: Church, colleges, and city
Fitch Program III Columbia
set Documentation README file Data Set Title: ROCK. Co-design workshops and self-built transformation of public space in Bologna with students and professionals. Urban regeneration of Piazza Scaravilli. The Malerbe experience
Mackay Archaeology: Stories and contemporary social context
Diamond Organic growth and the collective enterprise: Building on the work of Barbara Dockar-Drysdale to develop the new therapeutic task.
Wetzels New insights into the pathogenesis and the therapy of recurrent focal glomerulosclerosis
Balague et al. Activation of the Endoplasmic Reticulum (ER) Unfolded Protein Response (UPR) in Aggressive B-Cell Lymphomas.
Fehrsen Whither Now?
Turner et al. A Veterinary Tale of Two Buildings: Transformation to Meet the Needs of the Modern Student
Watson et al. Conditions of contract for the CERN underground works
Frankel et al. www. urologytimes. com
Campbell Regions, Territories and Strategies: Trends in Contemporary Practice and Thinking.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties